Physician profile
Margaret A Podlone
NPI 1447348123
$2,115.30
in general payments reported to CMS, 2019-2025
13 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $272 · 2022: $735 · 2023: $437 · 2024: $440 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,108.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $409.64 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $378.63 | 2022-2024 | Jardiance |
| Gilead Sciences, INC. | $228.18 | 2024-2025 | Epclusa |
| Neurocrine Biosciences, INC. | $135.64 | 2024 | Ingrezza |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $133.63 | 2022 | |
| Abbvie INC. | $124.99 | 2022 | |
| Madrigal Pharmaceuticals | $124.99 | 2025 | Rezdiffra |
| Biohaven Pharmaceuticals, INC. | $108.64 | 2021 | |
| Eisai INC. | $108.37 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $106.25 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $98.96 | 2023 | Fasenra |
| Sage Therapeutics, LLC | $95.84 | 2024 | |
| Coloplast Corp | $61.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Podlone listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.